ACAD
30.43
+0.34
+1.13%
AEMD
2.06
+0.01
+0.49%
APRI
1.08
-0.02
-1.82%
ARNA
24.05
+0.47
+1.99%
ATEC
1.725
-0.065
-3.631%
CNAT
6.04
0.00
0.00%
CRXM
0.169
0.00
0.00%
CYTX
1.11
-0.01
-0.89%
DXCM
69.52
-0.49
-0.70%
GNMK
12.05
-0.21
-1.71%
HALO
13.53
+0.27
+2.04%
ILMN
172.75
+0.78
+0.45%
INNV
0.116
-0.005
-4.132%
INO
6.01
0.00
0.00%
ISCO
1.23
-0.1
-7.52%
ISIS
57.56
0.00
0.00%
LGND
123.05
+2.36
+1.96%
LPTN
2.93
-2.93
-100.00%
MBVX
0.96
+0.03
+3.23%
MEIP
3.02
-0.05
-1.63%
MNOV
5.43
+0.12
+2.26%
MRTX
4.9
+0.25
+5.38%
MSTX
0.131
-0.007
-5.278%
NBIX
47.07
-0.72
-1.51%
NUVA
79.92
-1.19
-1.47%
ONCS
1.08
-0.04
-3.57%
ONVO
2.37
+0.05
+2.16%
OREX
2.47
-0.13
-5.00%
OTIC
18.9
+0.15
+0.80%
QDEL
37.71
-0.02
-0.05%
RCPT
231.96
0.00
0.00%
RGLS
0.98
+0.1
+11.36%
RMD
77
-1.03
-1.32%
SCIE
0
0.00
-14.2857%
SPHS
2.07
0.00
0.00%
SRNE
2.05
0.00
0.00%
TROV
0.96
-0.03
-3.03%
VICL
2.66
+0.01
+0.37%
VOLC
18
0.00
0.00%
ZGNX
13.4
-0.2
-1.47%
ACAD
30.43
+0.34
+1.13%
AEMD
2.06
+0.01
+0.49%
APRI
1.08
-0.02
-1.82%
ARNA
24.05
+0.47
+1.99%
ATEC
1.725
-0.065
-3.631%
CNAT
6.04
0.00
0.00%
CRXM
0.169
0.00
0.00%
CYTX
1.11
-0.01
-0.89%
DXCM
69.52
-0.49
-0.70%
GNMK
12.05
-0.21
-1.71%
HALO
13.53
+0.27
+2.04%
ILMN
172.75
+0.78
+0.45%
INNV
0.116
-0.005
-4.132%
INO
6.01
0.00
0.00%
ISCO
1.23
-0.1
-7.52%
ISIS
57.56
0.00
0.00%
LGND
123.05
+2.36
+1.96%
LPTN
2.93
-2.93
-100.00%
MBVX
0.96
+0.03
+3.23%
MEIP
3.02
-0.05
-1.63%
MNOV
5.43
+0.12
+2.26%
MRTX
4.9
+0.25
+5.38%
MSTX
0.131
-0.007
-5.278%
NBIX
47.07
-0.72
-1.51%
NUVA
79.92
-1.19
-1.47%
ONCS
1.08
-0.04
-3.57%
ONVO
2.37
+0.05
+2.16%
OREX
2.47
-0.13
-5.00%
OTIC
18.9
+0.15
+0.80%
QDEL
37.71
-0.02
-0.05%
RCPT
231.96
0.00
0.00%
RGLS
0.98
+0.1
+11.36%
RMD
77
-1.03
-1.32%
SCIE
0
0.00
-14.2857%
SPHS
2.07
0.00
0.00%
SRNE
2.05
0.00
0.00%
TROV
0.96
-0.03
-3.03%
VICL
2.66
+0.01
+0.37%
VOLC
18
0.00
0.00%
ZGNX
13.4
-0.2
-1.47%
Home » Archive by Category

Xconomy

If Budget Holds, NIH Precision Study Could Be Flush As Volunteers Arrive

May 4, 2017 – 2:30 am

Until this week, many U.S. government science agencies and programs seemed destined for a big haircut, plus the loss of a limb or two. That included the Precision Medicine Initiative, an ambitious…

[[Click headline to continue reading.]]

New San Diego Biotech Looks to Open Way for Anti-Cancer Drugs

May 3, 2017 – 4:00 am

In early 2002, the Finnish-born scientist Erkki Ruoslahti stepped down as CEO of what is now San Diego’s Sanford Burnham Prebys Medical Discovery Institute. He moved to Santa Barbara, CA, where he…

[[Click headline to continue reading.]]

CA Stem Cell Agency Chief Randy Mills to Leave After Three Years

May 2, 2017 – 11:58 am

[Updated 5/2/17, 7:30 p.m. ET. See below.] The head of California’s stem-cell agency is stepping down after three years on the job. C. Randall Mills, known as Randy, is leaving the agency to…

[[Click headline to continue reading.]]

Epic Sciences Advances Diagnostic for Late-Stage Prostate Cancer

April 30, 2017 – 8:44 pm

When San Diego’s Epic Sciences raised $30 million almost three years ago, CEO Murali Prahalad told me he saw a big opportunity to use the company’s technology as a diagnostic test to assess how well…

[[Click headline to continue reading.]]

Bio Roundup: Trumpcare Flails, Spinraza Sales, Batten OK & More

April 28, 2017 – 2:30 am

To judge the first 100 days of a new administration is, as many pundits have pointed out, an odd vestige of history, more convenient than significant. Which is why we’ll start this week’s…

[[Click headline to continue reading.]]

Gottlieb’s FDA Nomination Gets Committee Nod, Advances to Senate

April 27, 2017 – 7:53 am

Scott Gottlieb’s nomination to the top post of the FDA is on its way to the full U.S. Senate. The Senate Health, Education, Labor & Pensions Committee voted 14-9 on Thursday to approve Gottlieb’s…

[[Click headline to continue reading.]]

Will New Data Open “Bottlenecks” For Biogen’s Pricey Spine Drug?

April 26, 2017 – 9:30 am

Four months after its drug nusinersen (Spinraza) became the first ever approved to treat the rare genetic disease spinal muscular atrophy, Biogen (NASDAQ: BIIB) released study results Tuesday that…

[[Click headline to continue reading.]]

Forge Therapeutics Raises $15M to Take on Drug-Resistant Superbugs

April 25, 2017 – 11:06 am

One reason that drug-resistant “superbugs” are a growing healthcare problem is the hardiness of gram-negative bacteria, a type of bacteria whose characteristics render many antibiotics ineffective….

[[Click headline to continue reading.]]

While You Were Sleeping: ResMed Builds an Empire in the Cloud

April 25, 2017 – 5:00 am

Over the past 28 years or so, ResMed (NYSE: RMD) has built an empire around its respiratory devices for managing sleep apnea and other forms of “sleep-disordered breathing.” In the fiscal year that…

[[Click headline to continue reading.]]

Becton Dickinson Aims Beyond Diabetes with $24B Bard Deal

April 23, 2017 – 9:27 pm

In a medical technology merger with implications for the healthcare sector in the United States and beyond, Becton Dickinson is acquiring C.R. Bard for $24 billion to tap into the growing markets for…

[[Click headline to continue reading.]]